Introduction
Vitronectin (Vn),' also known as S protein (1) and serumspreading factor (2) , is a multifunctional 75-kD acidic glycoprotein present abundantly in plasma (200-500 gg/ml) and the extracellular matrix (2) . Plasma Vn functions in the complement cascade to prevent innocent bystander cytolysis by binding fluid phase C5b-7 and forming soluble, noncytolytic complexes (3) . Vn also forms complexes with thrombin and anti-thrombin III that, in vitro, retain thrombin catalytic activity (4) (5) (6) . Vn promotes the growth in tissue culture of multiple cell lines by mediating cell attachment to the substratum (7) , and a similar function in vivo is likely. Vn is present in the extracellular matrix of glomerular and aortic basement membrane, in the elastic layers of normal vessels walls, and in normal human dermis (2, 8) .
Recent cDNA cloning and amino acid sequencing reveal that Vn contains the tripeptide arg-gly-asp (RGD) and shares cell adhesion properties with other RGD-containing proteins (9) including fibrinogen, von Willebrand factor, and fibronectin. The latter three proteins have known roles in platelet aggregation and share a common receptor on the platelet surface (10). Fibrinogen binding to the platelet glycoprotein complex Ilb/Ila (GPIIb/IIIa) is critical for normal platelet aggregation (11) (12) (13) (14) . Von Willebrand factor binds to GPIb to mediate platelet adhesion, but is also capable of binding via an RGDcontaining domain to the GPIIb/IIIa complex (15, 16). Fibronectin also binds to GPIIb/IIIa on the activated platelet surface via an RGD domain (17) (18) (19) . Antibodies to GPIIb/IIIa, fibrinogen, and fibronectin are capable of inhibiting platelet aggregation, suggesting that these platelet adhesive proteins may participate in a macromolecular complex that is critical for normal platelet aggregation (19) (20) (21) (22) (23) .
GPIIb/IIIa on platelets is a promiscuous receptor for fibrinogen, von Willebrand factor, and fibronectin, and may also bind Vn (24) . The purified GP Ilb/Ila complex, when incorporated into liposomes, binds fibrinogen, fibronectin, von Willebrand factor, and Vn in an RGD-dependent manner (24) .
To investigate the role of Vn in platelet aggregation, we examined the binding of purified Vn to resting and to activated human platelets, and studied the effects of several antiVn antibodies on platelet aggregation.
Methods
Purification of Vn. Vn was purified by the method of Dahlback and Podack (25) . 1 Crossed immunoelectrophoresis. Vn was labeled with carrier-free '25I (Amersham Corp., Arlington Heights, IL) by the iodogen method (27) to a sp act of 1-2 X 106 cpm/,ug protein. The functional activity of 251I-Vn was assessed by measuring incorporation into SC5b-9 complexes. '251-Vn was added to serum before incubation with zymosan (10 mg/ml; Sigma Chemical Co., St. Louis, MO) at 370C for 1 h. Zymosan was removed by centrifugation at 3,000 rpm for 10 min and crossed immunoelectrophoresis was performed on the serum using polycional anti-C5 and anti-C9 antisera as precipitating antibodies for SC5b-9 (3). The agarose gel was washed extensively with Tris-buffered saline (10 mM Tris, 0.15 M NaCl, pH 7.4) and distilled water before drying and staining with 90% methanol, 7% acetic acid, 0.25% Coomassie blue (Bio-Rad Laboratories). The gels were subjected to autoradiography to demonstrate incorporation of functionally active '251I-Vn into SCSb-9 complexes.
Binding studies and time course. Gel-filtered human platelets were isolated from platelet-rich plasma collected in acid citrate dextrose containing PGEI and aspirin as previously described (28) . 100 AI of platelet suspensions (1 X 105/MI) were incubated with 251I-Vn in buffer containing 0.14 M NaCl, 2.7 mM KCl, 0.42 mM NaH2PO4, 12 mM NaHCO3, 5.5 mM glucose, 5 mM Hepes, 2 mM CaCl2, 1 mM MgCl2, and 1% albumin, pH 7.4 . Platelets were activated with 10 AtM epinephrine, 6 AM ADP, or 0. 10 U/ml thrombin without stirring. In thrombin experiments, the thrombin inhibitor pro-phe-arg chloromethylketone was added at 4 min to a final concentration of I AM. After incubation for 1 h, the platelets were spun through 400 A1 silicone oil and the bound radioactivity was quantitated (20) . In some experiments, binding was performed in the presence of 100 AM tetrapeptide arg-gly-aspser (RGDS) or arg-gly-glu-ser (RGES) (Peninsula Laboratories, Inc., Belmont, CA), 5 200 Ag/ml was incubated with thrombin-stimulated platelets for 30 min. Some platelet suspensions were diluted 10-or 50-fold in the same buffer for 10 min before measuring binding.
Immunoblotting. 108 gel-filtered resting platelets were pelleted by centrifugation at 2,000 g for 10 min and solubilized in buffer containing 1% SDS. Platelet extract, whole human plasma, and purified Vn were electrophoresed unreduced in a 7.5% SDS-polyacrylamide gel and transferred to nitrocellulose for immunoblotting (29) . The nitrocellulose was probed with polyclonal anti-Vn antibody followed by horseradish peroxidase-conjugated goat anti-rabbit IgG and developed with the substrate chloronaphthol. Similar studies were also performed using monoclonal anti-Vn antibodies as probes and the appropriate second antibodies. In other experiments, anti-Vn antibody was preabsorbed with Vn immobilized on nitrocellulose before use of the antibody as a probe for similar immunoblots.
Measurement ofthe surface expression ofendogenous platelet Vn.
The activation-dependent surface expression of platelet Vn was examined using '25I-monoclonal anti-Vn antibody 011-251 or a control monoclonal antibody. Antibody was labeled with 1251 by the iodogen method to a sp act of 106 cpm/,ug. 100 Al of gel-filtered platelets (1 X 105/I1A) in the presence of 1251_0 or an irrelevent '25I-labeled monoclonal antibody were stimulated with 10 !LM epinephrine or with 1 U/ml thrombin for 4 min without stirring. After incubation for 30 min the platelets were spun through silicone oil and the bound radioactivity in the platelet pellets was counted.
Platelet aggregation. Platelet aggregometry was performed using a Payton aggregometer (Payton Associates Ltd., Ontario, Canada) as previously described (20) . Platelet-rich plasma or gel-filtered platelets (1 X 106) were aggregated by thrombin (0.50, 0.25, or 0.10 U/ml), epinephrine (10, 5, or 2 AM), ADP (6 ALM), or collagen (150 5Og/ml) in the presence of control or monospecific polyclonal anti-Vn antibodies (100 Ig/ml) or monoclonal anti-Vn or control antibodies (10 ,ug/ml). Platelet secretion was monitored by measurement of ATP release from dense granules using a Lumi aggregometer (Chrono-Log Corp., Havertown, PA) as previously described (30) .
Results
Binding of 12SJ_ Vn to human platelets. The (Fig. 2) . Binding was reversible by 87% in infinite dilution studies (Fig. 2) . Binding to stimulated platelets was inhibited by 10 mM EDTA, 8 were solubilized, subjected to 7.5% SDS-PAGE under nonreducing conditions, and electroblotted to nitrocellulose paper. Blots were probed with monospecific polyclonal anti-Vn IgG (Fig. 5) 
ml). Polyclonal anti-Vn
IgG but not control IgG inhibited epinephrine-induced platelet aggregation in platelet-rich plasma (Fig. 7) . In addition, anti-Vn IgG but not control IgG inhibited ADP-and thrombin-, but not collagen-induced platelet aggregation in plateletrich plasma (data not shown). Similar results were obtained with the monoclonal anti-Vn antibodies 011-292 and 011-58 (10 ug/ml). In similar experiments with gel-filtered platelets, polyclonal anti-Vn and monoclonal anti-Vn antibodies 011-292 and 011-58 inhibited thrombin-induced aggregation (Fig. 7) . Control antibodies had no effect on aggregation. Several other monoclonal anti-Vn antibodies at the same concentration did not inhibit platelet aggregation, presumably because they recognized epitopes not critical to platelet function.
Discussion
Vn is a member of a large family of proteins that share a common RGD sequence and function in cell adhesion (9) . Its role in plasma in inhibiting the complement cascade has been well documented (3) . It also appears to have procoagulant activity and prevents the heparin-catalyzed inactivation of thrombin by anti-thrombin III (4) (5) (6) . Although Vn binds to cells via an RGD-containing domain and is related to other multifunctional adhesive glycoproteins, its function as a cell adhesion molecule in biological systems has not been well defined. In vitro, it can mediate attachment of cells to plastic surfaces (7) , but its role in the extracellular matrix or in other biological systems has been unclear. Our data demonstrate specific and saturable binding of purified Vn to the activated platelet surface with a Kd of Since the initial submission ofthis paper, the binding of Vn to activated platelets has also been reported (33) . In contrast to our data, only 5,000 sites/platelet were identified, and the binding measured was not reversible. Both activation-independent manner, and this is not true of the Vn binding to platelets that we have characterized. In addition, a monoclonal antibody to the endothelial cell Vn receptor (LM609) had no measurable effect on Vn expression on the platelet surface. We conclude that GPIIb/IIIa and not the recently reported endothelial cell Vn receptor is responsible for the activation-dependent platelet Vn binding that we have observed.
Platelet activation leads to a conformational or microenvironmental alteration of the GPIIb/IIIa complex, which results in the induction of binding sites for several ligands (34). Fibrinogen appears to be the major ligand for the GPIIb/IIIa complex, but fibronectin and von Willebrand factor also bind to this complex on the platelet surface (41) . Antibodies to fibrinogen and fibronectin inhibit platelet aggregation, as do antibodies directed against the GPIIb/IIIa complex (20, 21, 42) . Recent evidence suggests that thrombospondin, another alpha granule protein, participates in a macromolecular complex on the platelet surface between fibrinogen bound to GPIIb/IIIa and a specific platelet membrane thrombospondin receptor (43, 44) . Antibodies to thrombospondin, as well as antibodies directed at the receptor inhibit platelet aggregation, and interfere with fibrinogen binding (20, 43) . Although Vn can form disulfide-linked dimers and under these conditions may form a bivalent ligand linking platelets, our autoradiography data suggest that platelet bound Vn is monomeric. Vn, like fibronectin, and in contrast to thrombospondin, fibrinogen, and von Willebrand factor is univalent with respect to the platelet surface. The binding site is RGD dependent and there is only one RGD per Vn molecule. Therefore, the role of Vn in supporting platelet aggregation is not likely to be that of a primary ligand like fibrinogen. The mechanism by which antibodies directed against Vn inhibit platelet aggregation are not clear. However, since several monoclonal antibodies to Vn had no effect on platelet aggregation, a specific domain of Vn appears to be important in this regard.
Our data suggest that in vivo Vn may play a role in platelet aggregation, perhaps by participating in the formation of a large complex on the platelet surface composed of fibrinogen, von Willebrand factor, thrombospondin, and fibronectin. Fibrinogen binding to OPlIb/Illa is critical for normal platelet aggregation. The stabilization of the platelet aggregate appears to occur secondary to release of platelet granule contents. Anti-Vn antibody prevents the second wave of platelet aggregation in both platelet-rich plasma and gel-filtered platelets. Similar data have been published with antibodies to thrombospondin (43, 45, 46) . Secreted Vn, released upon platelet stimulation like thrombospondin, or bound to the platelet surface from plasma, may serve to stabilize the platelet aggregate. Recently, the binding of Vn to other cell types has been described and a variety of cellular receptors have been identified (35, 47) . The role of Vn in mediating platelet-cell or cellcell interactions remains to be defined. Vn in the extracellular matrix may facilitate platelet adhesion to exposed subendothelium. Endogenous platelet Vn may serve to stabilize the platelet-platelet interactions when platelets are activated and platelet granule contents are released. Recent data have demonstrated platelet activation by the cytolytic complement complex C5b-9 (48) . Platelet Vn may also serve to inactivate C5b-9 that binds to innocent bystander platelets in areas of inflammation and complement activation.
